Chronic Obstructive Pulmonary Disease (COPD) is a chronic respiratory condition affecting 380 million patients worldwide leading to severe morbidity and mortality. These patients are vulnerable for recurrent infection of the airways leading to exacerbations or lung attacks, characterized by severe shortness of breath and irreversible lung damage. These lung attacks decrease the quality of life significantly and could ultimately lead to death. Therefore, prevention or shortening the lung attacks is pivotal to maintain the quality of life for COPD patients, for which early diagnosis of infection is required. Current diagnostic methods take 2 to 3 days, while the patient requires treatment within hours upon arrival in the hospital. As a consequence most patients are treated empirically with broad spectrum antibiotics.
X-Heal Diagnostics presents the solution for this unmet need with the X-halyzer technology. This patented diagnostic platform allows specific detection of bacteria from exhaled air within 1 hour, directly enabling targeted treatment.
The ambition of X-heal Diagnostics is to market the X-halyzer technology for different indications and target groups, such as the diagnosis of lung infections in cystic fibrosis patients and diagnosis of tuberculosis. To achieve this goal, we need an initial investment of 2 Million euro to perform clinical trials and certify assays for new indications.